Skip to the rundown
GetYourBrief Biotech desk · week of Oct 19
Search

Week brief · October 19 to 25, 2026

Biotech news, week of October 19, 2026

In the week of October 19 to 25, 2026 the Biotech desk recorded 6 news events on 2 days. Clinical trial led with 3.

The most covered stories of the week

  1. Oct 19 GSK's Jemperli wins accelerated FDA approval in rectal cancer 6
  2. Oct 19 Evaxion reports no tumor progression at three years in EVX-01 trial 3
  3. Oct 20 AstraZeneca, Oracle sign non-binding AI deal to boost trial recruitment 2
  4. Oct 20 Myriad to sell prenatal testing business to Labcorp for $210M 2
  5. Oct 20 contractpharma.com: “Hansoh Pharma, Roche Join to Accelerate Global Novel ADC Development” 2
  6. Oct 20 Planned newborns hepatitis B trial stalls after police seize doses 2

Monday, October 19, 2026

  1. 01

    GSK's Jemperli wins accelerated FDA approval in rectal cancer

    6 outlets · first: Investing.com UK Fda approval

    Machine summary GSK's PD-1 inhibitor dostarlimab received accelerated FDA approval in previously untreated, locally advanced rectal cancer for patients with dMMR/MSI-H tumors, according to MedPage Today and Fierce Pharma. The decision rests on the AZUR-1 trial, which reports a high complete response rate, with most treated patients avoiding surgery.

    Reported by Oncology Nursing News, Fierce Pharma, MedPage Today, Investing.com UK, CancerNetwork and Cure Today.

    • GSK
    • AZUR-1
    • dMMR/MSI-H
    • Jemperli (dostarlimab)

    Full coverage: every report, when each was published, and who was named (6 outlets)

  2. 02

    Evaxion reports no tumor progression at three years in EVX-01 trial

    3 outlets · first: Stock Titan Clinical trial

    Machine summary Evaxion announced three-year follow-up results from its phase 2 trial of EVX-01 in advanced melanoma, stating that all patients maintained the responses seen at two years and that no tumor progression was observed. The company reported earlier that the two-year data showed a 75% objective response rate with 25% complete responses, tumor reduction in 15 of 16 patients, and T-cell responses to 86% of vaccine neoantigens. CSO and COO Birgitte Rønø said the data package is a good foundation for potential partnership discussions.

    1. At the two-year follow-up presented at ESMO 2025, Evaxion reported a 75% objective response rate in the trial, with 25% of patients achieving a complete response
    2. Tumor reduction in target lesions was observed in 15 of the 16 patients enrolled, and 54% of patients had a deepened response after EVX-01 treatment began, according to the company
    3. According to Evaxion, EVX-01 triggered an immune response in every patient, and 86% of the vaccine neoantigens produced strong, specific T-cell responses as measured at the two-year point.
    4. According to the company's announcement, in year three of treatment, patients got EVX-01 alone.
    5. The three-year data and new immune data are scheduled for a poster session at ESMO Congress 2026 in Madrid, October 23 to 27, 2026

    Reported by Stock Titan, manilatimes.net and Investing.com.

    • EVX-01
    • Evaxion
    • ESMO Congress 2026

Tuesday, October 20, 2026

4 events. The full rundown for October 20, 2026. The most covered:

  1. 05:31 UTC AstraZeneca, Oracle sign non-binding AI deal to boost trial recruitment 2
  2. 13:27 UTC Myriad to sell prenatal testing business to Labcorp for $210M 2
  3. 16:06 UTC contractpharma.com: “Hansoh Pharma, Roche Join to Accelerate Global Novel ADC Development” 2

Summaries and key facts are machine summaries of the reports linked with them; outlets, times and counts come from those reports. How a rundown is built.

What kind of news was it?

  1. Clinical trial 3
  2. Fda approval 1
  3. Acquisition 1
  4. Pharma 1

Sources: the outlets' reports linked on this page; counts and times from GetYourBrief's record of those reports (methodology).